Recently, we reported that TNKS1/2 inhibition potentiated the effect of PD-1 antibody–based immunotherapy against murine B16-F10 melanoma tumors, an anti–PD-1–resistant model showing β-catenin–induced immune evasion (39). This evidence concerns the gene PDCD1 and melanoma.